{"product_id":"cholesterol-and-heart-disease-death-insights-from-a-study-of-4-5-million-veterans","title":"Cholesterol and Heart Disease Death: Insights From a Study of 4.5 Million Veterans","description":"\u003cp\u003eThis large-scale study of more than 4.4 million U.S. military veterans examined how blood cholesterol levels relate to the risk of dying from coronary heart disease. After carefully accounting for age, existing medical conditions, medication use, and other factors, researchers found that the risk of heart disease death increases steadily and continuously as total cholesterol rises above 180 mg\/dL. The long-debated \"cholesterol paradox\" (where very low cholesterol seemed to increase risk) was explained by reverse causality: older and sicker veterans tended to have low cholesterol because of underlying disease, not because low cholesterol is harmful. These findings strongly support the long-standing \"lipid hypothesis\" that lower cholesterol levels are better for heart health, even when those low levels are achieved through statin medications.\u003c\/p\u003e\n\n\u003ch1\u003eCholesterol and Heart Disease Death: Insights From a Study of 4.5 Million Veterans\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: The Longstanding Cholesterol Debate\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#participants\"\u003eStudy Participants: A Snapshot at Baseline\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: The Shape of the Cholesterol–Heart Disease Relationship\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#age\"\u003eAge Matters: Different Patterns in Different Age Groups\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#heart-disease\"\u003ePreexisting Heart Disease: Similar Patterns, Higher Overall Risk\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#statins\"\u003eStatin Medications and the Cholesterol Connection\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: Practical Advice for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAmong 4.4 million U.S. veterans, heart disease death risk rose continuously as total cholesterol increased above 180 mg\/dL.\u003c\/li\u003e\n\u003cli\u003eAfter full adjustment, low cholesterol carried no increased heart disease death risk, dissolving the cholesterol paradox.\u003c\/li\u003e\n\u003cli\u003eThe apparent danger of low cholesterol was reverse causality: older and sicker veterans had low cholesterol due to disease.\u003c\/li\u003e\n\u003cli\u003eStatin-induced low cholesterol was not harmful; starting statins attenuated the risk linked to high baseline cholesterol.\u003c\/li\u003e\n\u003cli\u003eHigh cholesterol raised risk in all ages, but the strongest relative risk was in veterans aged 18–45.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: The Longstanding Cholesterol Debate\u003c\/h2\u003e\n\n\u003cp\u003eFor decades, scientists have debated whether lower blood cholesterol is always better for heart health. The \u003cstrong\u003elipid hypothesis\u003c\/strong\u003e — the theory that lower blood cholesterol leads to a reduced risk of coronary heart disease (CHD) — has been a cornerstone of cardiovascular prevention. But the picture has been complicated.\u003c\/p\u003e\n\n\u003cp\u003eReports across different populations have shown varying relationships between cholesterol and death. Some studies described a \u003cstrong\u003elinear relationship\u003c\/strong\u003e (risk rises steadily with cholesterol), while others found what researchers call \u003cstrong\u003eU-shaped\u003c\/strong\u003e, \u003cstrong\u003eL-shaped\u003c\/strong\u003e, or \u003cstrong\u003eV-shaped\u003c\/strong\u003e patterns. These shapes suggest that the lowest cholesterol levels might actually be associated with higher risk — a finding that puzzled scientists and challenged the lipid hypothesis.\u003c\/p\u003e\n\n\u003cp\u003eIn the 1980s, before statin drugs were widely used, a famous large screening study of middle-aged men showed a continuous, graded relationship between serum cholesterol and CHD risk that persisted even after adjusting for age, race, income, smoking status, blood pressure, diabetes, and prior heart attacks. More recent data from the \u003cstrong\u003eCholesterol Treatment Trialists' Collaboration\u003c\/strong\u003e has shown that statin therapy reduces the risk of cardiovascular events even in people with low total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C, the \"bad\" cholesterol).\u003c\/p\u003e\n\n\u003cp\u003eThe idea that low cholesterol might somehow be dangerous has persisted, particularly among older individuals and patients with chronic conditions such as heart failure or kidney failure. In these \u003cstrong\u003ecatabolic conditions\u003c\/strong\u003e (conditions where the body breaks down more tissue than it builds), cholesterol levels may drop because of the disease itself, chronic inflammation, or malnutrition. This phenomenon is sometimes called \u003cstrong\u003ereverse epidemiology\u003c\/strong\u003e — where a risk factor appears to behave differently in certain patient groups, not because the risk factor is actually protective, but because the underlying disease is driving both the risk factor and the outcome.\u003c\/p\u003e\n\n\u003cp\u003eThis debate matters for public health. The U.S. Preventive Services Task Force recently released updated recommendations for statin therapy in primary prevention of cardiovascular disease. Compared with the 2018 American Heart Association\/American College of Cardiology guidelines, the newer recommendations reduce eligibility for statin therapy by \u003cstrong\u003e15%\u003c\/strong\u003e among U.S. adults, including \u003cstrong\u003e37% fewer patients with diabetes aged 40 to 75 years\u003c\/strong\u003e who would qualify. Understanding whether the \"cholesterol paradox\" is real or an artifact of flawed analysis is critical for both clinical practice and public health policy.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003ch3\u003eStudy Design and Data Source\u003c\/h3\u003e\n\u003cp\u003eThis was a \u003cstrong\u003eprospective cohort study\u003c\/strong\u003e — meaning researchers identified a large group of people, measured their cholesterol levels at the start of the study, and then followed them forward in time to see who developed or died from heart disease. The study used data from the \u003cstrong\u003eVeterans Health Administration (VHA)\u003c\/strong\u003e, which provides medical care for more than 21 million veterans nationwide.\u003c\/p\u003e\n\n\u003cp\u003eThe research team extracted electronic health record (EHR) data from the VA Corporate Data Warehouse, identifying veterans who had at least one outpatient lipid panel (cholesterol blood test) between 2002 and 2007. The baseline date for each participant was the date of their first outpatient lipid result during that period. Follow-up continued until December 31, 2018, or until death, whichever came first.\u003c\/p\u003e\n\n\u003ch3\u003eExposure: Measuring Cholesterol\u003c\/h3\u003e\n\u003cp\u003eA panel of clinicians reviewed laboratory values across all VA locations and adjudicated discrepancies to ensure consistent measurements. Only outpatient blood lipid data were used. Because fasting status (whether the patient had eaten before the blood draw) was uncertain, the researchers focused on \u003cstrong\u003etotal cholesterol (TC)\u003c\/strong\u003e and \u003cstrong\u003ehigh-density lipoprotein cholesterol (HDL-C, the \"good\" cholesterol)\u003c\/strong\u003e, as both are reliable predictors of CHD mortality whether the patient is fasting or not.\u003c\/p\u003e\n\n\u003cp\u003eParticipants were divided into \u003cstrong\u003e10 total cholesterol groups\u003c\/strong\u003e (measured in mg\/dL):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLess than 120\u003c\/li\u003e\n  \u003cli\u003e120–139\u003c\/li\u003e\n  \u003cli\u003e140–159\u003c\/li\u003e\n  \u003cli\u003e160–179\u003c\/li\u003e\n  \u003cli\u003e180–199 (used as the reference or \"normal\" group)\u003c\/li\u003e\n  \u003cli\u003e200–219\u003c\/li\u003e\n  \u003cli\u003e220–239\u003c\/li\u003e\n  \u003cli\u003e240–259\u003c\/li\u003e\n  \u003cli\u003e260–279\u003c\/li\u003e\n  \u003cli\u003e280 or higher\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOutcome: Defining Heart Disease Death\u003c\/h3\u003e\n\u003cp\u003eThe outcome of interest was \u003cstrong\u003ecoronary heart disease death\u003c\/strong\u003e, defined as CHD listed as the primary cause of death. Outcomes were determined using data from the VHA EHR, the Centers for Medicare and Medicaid Services, and the National Death Index.\u003c\/p\u003e\n\n\u003ch3\u003eCovariates: Accounting for Other Risk Factors\u003c\/h3\u003e\n\u003cp\u003eThe researchers collected detailed information on demographics (age, sex, race) from the EHR. They also identified \u003cstrong\u003e13 comorbidities\u003c\/strong\u003e (chronic diseases diagnosed within 3 years before baseline) using International Classification of Diseases, Ninth Revision (ICD-9) codes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eHypertension (high blood pressure)\u003c\/li\u003e\n  \u003cli\u003eDiabetes\u003c\/li\u003e\n  \u003cli\u003eAtrial fibrillation (irregular heart rhythm)\u003c\/li\u003e\n  \u003cli\u003eHeart failure\u003c\/li\u003e\n  \u003cli\u003eAnemia\u003c\/li\u003e\n  \u003cli\u003eCoronary artery disease\u003c\/li\u003e\n  \u003cli\u003eCancer\u003c\/li\u003e\n  \u003cli\u003eStroke\u003c\/li\u003e\n  \u003cli\u003eDementia\u003c\/li\u003e\n  \u003cli\u003eDepression\u003c\/li\u003e\n  \u003cli\u003eKidney disease\u003c\/li\u003e\n  \u003cli\u003eLiver disease or cirrhosis\u003c\/li\u003e\n  \u003cli\u003eLung disease (chronic obstructive pulmonary disease or asthma)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSmoking status (never, former, current, or missing) was determined using EHR data combined with a modified algorithm that generates a probabilistic model of smoking behavior. Body mass index (BMI) was recorded. A national zip code database showing the fraction of adults below U.S. poverty limits was used as a geographic indicator of low-income status. Statin use was tracked at multiple time points: no usage recorded, initiated before or at baseline, within 2 years of follow-up, or after 2 years of follow-up.\u003c\/p\u003e\n\n\u003ch3\u003eStatistical Analysis: Building the Models\u003c\/h3\u003e\n\u003cp\u003eThe researchers used \u003cstrong\u003eCox proportional hazards regression\u003c\/strong\u003e, a standard statistical method for analyzing time-to-event data, to estimate the \u003cstrong\u003ehazard ratio (HR)\u003c\/strong\u003e and 95% confidence interval (CI) for CHD death, with the 180–199 mg\/dL cholesterol group serving as the reference category. They built three progressively more comprehensive models:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModel 1:\u003c\/strong\u003e Adjusted for age (continuous), sex, race, and smoking status.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModel 2:\u003c\/strong\u003e Additionally adjusted for timing of statin therapy initiation, body mass index, baseline hypertension, and baseline diabetes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModel 3 (the final model):\u003c\/strong\u003e Further adjusted for HDL-C (continuous) and the presence of 11 chronic diseases. This model also applied a \u003cstrong\u003e2-year lag analysis\u003c\/strong\u003e, meaning deaths occurring within the first 2 years of follow-up were censored (excluded) to reduce the potential for reverse causality — the possibility that undiagnosed disease at the start of the study was lowering cholesterol levels and also increasing death risk.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eTo flexibly model the dose–response relationship, the team used \u003cstrong\u003erestricted cubic spline regression\u003c\/strong\u003e with 3 knots (specific points along the cholesterol range where the curve is allowed to flex). Nonlinearity was tested using the likelihood ratio test. Sensitivity analyses included adjusting for income and socioeconomic status, stratifying by the presence of heart disease at baseline, and evaluating LDL-C, non-HDL cholesterol, and triglycerides separately. All analyses used SAS 9.3, with P values ≤0.05 considered statistically significant.\u003c\/p\u003e\n\n\u003ch2 id=\"participants\"\u003eStudy Participants: A Snapshot at Baseline\u003c\/h2\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e4,467,942 adult veterans\u003c\/strong\u003e nationwide had a complete lipid profile at baseline and were included in the study. This is one of the largest studies of cholesterol and heart disease death ever conducted.\u003c\/p\u003e\n\n\u003cp\u003eThe distribution of total cholesterol levels was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e9.6%\u003c\/strong\u003e had very low TC (≤140 mg\/dL)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e33.0%\u003c\/strong\u003e had low TC (140–179 mg\/dL)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e19.6%\u003c\/strong\u003e had normal TC (180–199 mg\/dL)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e26.2%\u003c\/strong\u003e had high TC (200–239 mg\/dL)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e11.6%\u003c\/strong\u003e had very high TC (≥240 mg\/dL)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSome striking patterns emerged in baseline characteristics. Veterans in the \u003cstrong\u003elowest cholesterol group\u003c\/strong\u003e (TC \u0026lt;120 mg\/dL) tended to have the \u003cstrong\u003elowest HDL-C levels\u003c\/strong\u003e (average 38.2 mg\/dL compared with 57.1 mg\/dL in the highest TC group), the \u003cstrong\u003egreatest average age\u003c\/strong\u003e (66.1 years vs. 58.6 years), a \u003cstrong\u003ehigher likelihood of having started statin therapy before baseline\u003c\/strong\u003e (42.0% vs. 24.0% for the \u0026lt;120 mg\/dL group), and the \u003cstrong\u003ehighest prevalence of nearly every comorbidity\u003c\/strong\u003e measured.\u003c\/p\u003e\n\n\u003cp\u003eThis baseline profile is the first clue to the \"cholesterol paradox.\" The veterans with the lowest cholesterol were, on average, older and sicker than those with higher cholesterol. They had more hypertension, diabetes, coronary artery disease, heart failure, cancer, kidney disease, and lung disease. This is exactly the pattern expected if \u003cstrong\u003ereverse causality\u003c\/strong\u003e were at work: serious illness lowers cholesterol, rather than low cholesterol causing harm.\u003c\/p\u003e\n\n\u003cp\u003eMedication patterns also differed by cholesterol group. More than one-third of veterans with low or very low TC (34.9% and 38.3%, respectively) had initiated statin therapy before or at baseline, while more than 40% of veterans with very high TC (≥280 mg\/dL) started statin therapy within the first 2 years of follow-up. This reflects appropriate clinical practice — treating high cholesterol with medication — but it also means that a person's cholesterol group at baseline doesn't necessarily reflect their lifetime exposure.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: The Shape of the Cholesterol–Heart Disease Relationship\u003c\/h2\u003e\n\n\u003cp\u003eThe relationship between total cholesterol and the risk of dying from heart disease changed depending on how thoroughly the researchers adjusted for other factors. This progression is itself a major finding.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eModel 1\u003c\/strong\u003e (adjusting only for age, sex, race, and smoking) produced a \u003cstrong\u003eV-shaped\u003c\/strong\u003e relationship, with the lowest risk of CHD death at a TC of about 207 mg\/dL. Both lower and higher cholesterol appeared to carry increased risk.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eModel 2\u003c\/strong\u003e (adding adjustments for BMI, statin use, diabetes, and hypertension) produced a \u003cstrong\u003eU-shaped\u003c\/strong\u003e relationship, with the lowest risk at TC levels of 200 to 215 mg\/dL, and elevated risk at both the low and high ends of the cholesterol spectrum.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eModel 3\u003c\/strong\u003e (the comprehensive model with the 2-year lag analysis and adjustments for HDL-C and 11 chronic diseases) produced a \u003cstrong\u003eJ-shaped\u003c\/strong\u003e relationship that tells a much clearer story: the risk of CHD death was \u003cstrong\u003eflat for TC below 180 mg\/dL\u003c\/strong\u003e — meaning low cholesterol was not associated with any increased risk — and then increased continuously, in a graded fashion, as cholesterol rose above 180 mg\/dL.\u003c\/p\u003e\n\n\u003cp\u003eCompared with veterans whose TC was 180–199 mg\/dL (the reference group), the fully adjusted hazard ratios for CHD death were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTC 200–219 mg\/dL: \u003cstrong\u003e1.03\u003c\/strong\u003e (95% CI, 1.02–1.04) — a 3% higher risk\u003c\/li\u003e\n  \u003cli\u003eTC 220–239 mg\/dL: \u003cstrong\u003e1.07\u003c\/strong\u003e (95% CI, 1.06–1.09) — a 7% higher risk\u003c\/li\u003e\n  \u003cli\u003eTC 240–259 mg\/dL: \u003cstrong\u003e1.15\u003c\/strong\u003e (95% CI, 1.13–1.18) — a 15% higher risk\u003c\/li\u003e\n  \u003cli\u003eTC 260–279 mg\/dL: \u003cstrong\u003e1.25\u003c\/strong\u003e (95% CI, 1.22–1.28) — a 25% higher risk\u003c\/li\u003e\n  \u003cli\u003eTC ≥280 mg\/dL: \u003cstrong\u003e1.45\u003c\/strong\u003e (95% CI, 1.42–1.49) — a 45% higher risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese hazard ratios mean, for example, that a veteran with a total cholesterol of 280 mg\/dL or higher was \u003cstrong\u003e45% more likely\u003c\/strong\u003e to die from coronary heart disease during the follow-up period than a similar veteran with cholesterol in the 180–199 mg\/dL range, after accounting for all other measured risk factors.\u003c\/p\u003e\n\n\u003cp\u003eThe results were \u003cstrong\u003econsistent between men and women\u003c\/strong\u003e (P for interaction between TC and sex = 0.41), meaning the pattern held true across genders. Adjusting for income and socioeconomic status in sensitivity analyses did not materially change the results.\u003c\/p\u003e\n\n\u003ch2 id=\"age\"\u003eAge Matters: Different Patterns in Different Age Groups\u003c\/h2\u003e\n\n\u003cp\u003eOne of the most important contributions of this study is its detailed analysis of how age influences the cholesterol–heart disease relationship. The researchers divided veterans into three age groups and found strikingly different patterns:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAges 18–45 years:\u003c\/strong\u003e J-J-J-shaped pattern\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAges 45–64 years:\u003c\/strong\u003e V-U-J-shaped pattern\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAges 65 years and older:\u003c\/strong\u003e L-U-J-shaped pattern\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eStatistical testing confirmed that age significantly modified the relationship between cholesterol and heart disease death (\u003cstrong\u003eP for interaction between TC and age group \u0026lt;0.001\u003c\/strong\u003e), meaning the effect of cholesterol on CHD death genuinely differs across age groups.\u003c\/p\u003e\n\n\u003cp\u003eComparing veterans with normal TC (180–199 mg\/dL) to those with higher levels, the hazard ratios for CHD death were:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eYounger veterans (ages 18–45):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTC 200–219: 1.03 (95% CI, 0.92–1.15)\u003c\/li\u003e\n  \u003cli\u003eTC 220–239: 1.17 (95% CI, 1.04–1.32)\u003c\/li\u003e\n  \u003cli\u003eTC 240–259: 1.40 (95% CI, 1.23–1.59)\u003c\/li\u003e\n  \u003cli\u003eTC 260–279: 1.32 (95% CI, 1.13–1.55)\u003c\/li\u003e\n  \u003cli\u003eTC ≥280: 1.96 (95% CI, 1.71–2.24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eYounger veterans with very high cholesterol (≥280 mg\/dL) had nearly \u003cstrong\u003edouble the risk\u003c\/strong\u003e of dying from heart disease compared with those in the normal range.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMiddle-aged veterans (ages 45–64):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTC 200–219: 1.02 (95% CI, 1.00–1.05)\u003c\/li\u003e\n  \u003cli\u003eTC 220–239: 1.08 (95% CI, 1.05–1.11)\u003c\/li\u003e\n  \u003cli\u003eTC 240–259: 1.17 (95% CI, 1.14–1.21)\u003c\/li\u003e\n  \u003cli\u003eTC 260–279: 1.25 (95% CI, 1.20–1.29)\u003c\/li\u003e\n  \u003cli\u003eTC ≥280: 1.41 (95% CI, 1.36–1.46)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOlder veterans (ages 65 and above):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTC 200–219: 1.03 (95% CI, 1.01–1.04)\u003c\/li\u003e\n  \u003cli\u003eTC 220–239: 1.06 (95% CI, 1.04–1.08)\u003c\/li\u003e\n  \u003cli\u003eTC 240–259: 1.12 (95% CI, 1.09–1.14)\u003c\/li\u003e\n  \u003cli\u003eTC 260–279: 1.21 (95% CI, 1.18–1.25)\u003c\/li\u003e\n  \u003cli\u003eTC ≥280: 1.34 (95% CI, 1.29–1.99)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe pattern was consistent: the risk of dying from CHD rises progressively with higher cholesterol levels in every age group. However, the magnitude of the effect was most dramatic in \u003cstrong\u003eyounger veterans\u003c\/strong\u003e. This may reflect the fact that younger individuals with very high cholesterol have a more severe genetic or lifelong cholesterol burden, while in older adults, competing health risks and the cholesterol-lowering effects of chronic disease weaken the observed association.\u003c\/p\u003e\n\n\u003cp\u003eThe reversal of the apparent \"danger\" of low cholesterol in the older group after full adjustment — where the L-shaped curve transformed into a J-shaped curve — supports the researchers' conclusion that \u003cstrong\u003ereverse causality, especially among older participants, accounted for the high risk of CHD death seen in those with low cholesterol levels.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2 id=\"heart-disease\"\u003ePreexisting Heart Disease: Similar Patterns, Higher Overall Risk\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers also examined whether having heart disease at baseline changed the relationship. They stratified the analysis into veterans with heart disease (atrial fibrillation, heart failure, or coronary artery disease diagnosed before baseline) and those without.\u003c\/p\u003e\n\n\u003cp\u003eAmong veterans \u003cstrong\u003ewith heart disease\u003c\/strong\u003e at baseline, compared with those with normal TC (180–199 mg\/dL), the hazard ratios for CHD death were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTC 200–219: 1.02 (95% CI, 1.00–1.03)\u003c\/li\u003e\n  \u003cli\u003eTC 220–239: 1.06 (95% CI, 1.04–1.08)\u003c\/li\u003e\n  \u003cli\u003eTC 240–259: 1.13 (95% CI, 1.10–1.16)\u003c\/li\u003e\n  \u003cli\u003eTC 260–279: 1.23 (95% CI, 1.19–1.28)\u003c\/li\u003e\n  \u003cli\u003eTC ≥280: 1.42 (95% CI, 1.37–1.47)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAmong veterans \u003cstrong\u003ewithout heart disease\u003c\/strong\u003e at baseline, the corresponding hazard ratios were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTC 200–219: 1.04 (95% CI, 1.02–1.06)\u003c\/li\u003e\n  \u003cli\u003eTC 220–239: 1.10 (95% CI, 1.08–1.13)\u003c\/li\u003e\n  \u003cli\u003eTC 240–259: 1.20 (95% CI, 1.17–1.23)\u003c\/li\u003e\n  \u003cli\u003eTC 260–279: 1.30 (95% CI, 1.26–1.34)\u003c\/li\u003e\n  \u003cli\u003eTC ≥280: 1.54 (95% CI, 1.49–1.60)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBoth groups showed the same J-shaped pattern — flat risk at low cholesterol, rising risk at higher cholesterol — but the effect of high cholesterol was \u003cstrong\u003emore pronounced in veterans without preexisting heart disease\u003c\/strong\u003e (P for interaction \u0026lt;0.001). This makes sense: in people who already have heart disease, the disease itself is the dominant driver of mortality, somewhat diluting the relative contribution of cholesterol levels.\u003c\/p\u003e\n\n\u003ch2 id=\"statins\"\u003eStatin Medications and the Cholesterol Connection\u003c\/h2\u003e\n\n\u003cp\u003eA critical question for patients is whether cholesterol-lowering medication changes the story. The researchers stratified the analysis by statin use and found that the J-shaped pattern held across all groups, but with important nuances.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eVeterans who did not use statins\u003c\/strong\u003e and \u003cstrong\u003eveterans who used statins at or before baseline\u003c\/strong\u003e both showed similar J-shaped relationships between TC and CHD death. Among veterans not using statins, the hazard ratio for CHD death with TC ≥280 mg\/dL compared with normal TC (180–199 mg\/dL) was \u003cstrong\u003e1.83 (95% CI, 1.68–1.99)\u003c\/strong\u003e — nearly double the risk. Among those who had started statin therapy at or before baseline, the hazard ratio for TC ≥280 mg\/dL was lower: \u003cstrong\u003e1.45 (95% CI, 1.40–1.51)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eA \u003cstrong\u003eslight U-shaped relationship\u003c\/strong\u003e was seen among veterans who started statin therapy after baseline. Higher baseline TC was associated with higher CHD mortality risk, but the effect was \u003cstrong\u003eattenuated\u003c\/strong\u003e (weakened) among veterans who initiated statins during follow-up. This suggests that starting statin therapy reduced the risk associated with high cholesterol.\u003c\/p\u003e\n\n\u003cp\u003eThese findings are reassuring and clinically important: \u003cstrong\u003ethe lipid hypothesis held true even when low cholesterol was achieved through statin medication.\u003c\/strong\u003e In other words, low cholesterol caused by statins is not harmful — it is associated with reduced, not increased, heart disease death risk. The idea that statin-induced low cholesterol might somehow be dangerous was not supported by this study.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study provides strong, large-scale evidence supporting the lipid hypothesis: \u003cstrong\u003elower blood cholesterol is associated with reduced coronary heart disease risk, and higher cholesterol is associated with increased risk in a continuous, graded fashion.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eFor patients, several key messages emerge:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe \"cholesterol paradox\" appears to be a statistical illusion.\u003c\/strong\u003e When studies fail to adequately adjust for underlying illness, age, and other confounders, low cholesterol can appear harmful. This study shows that after rigorous adjustment, low cholesterol carries no excess heart disease death risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReverse causality explains the apparent danger of low cholesterol.\u003c\/strong\u003e Older and sicker patients tend to have lower cholesterol because of their diseases, not because low cholesterol is harmful. The diseases themselves — heart failure, cancer, kidney disease, chronic inflammation — drive both the low cholesterol and the higher death rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigher cholesterol gradationally increases risk.\u003c\/strong\u003e There is no threshold effect. Risk rises steadily from 180 mg\/dL upward, reinforcing the importance of keeping cholesterol in a healthy range.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStatin therapy is not something to fear regarding low cholesterol.\u003c\/strong\u003e Patients whose cholesterol is lowered with statins or other lipid-lowering medications do not face a paradoxical increase in risk. The benefit of lowering cholesterol was confirmed across all statin-use groups.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge is an important modifier.\u003c\/strong\u003e The relative risk associated with high cholesterol was strongest in younger veterans (ages 18–45), where TC ≥280 mg\/dL was associated with nearly double the risk of CHD death. This underscores the importance of addressing high cholesterol early in life.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors state plainly: \u003cstrong\u003e\"Clinical practice based on the lipid hypothesis should not be challenged.\"\u003c\/strong\u003e For doctors and patients alike, this means the foundational principle of cholesterol management — that lowering cholesterol reduces heart disease risk — remains firmly supported by evidence.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eWhile this is one of the largest and most comprehensive studies of its kind, it has limitations that should be acknowledged:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObservational design:\u003c\/strong\u003e Because this is an observational cohort study (not a randomized controlled trial), it can demonstrate associations but cannot prove causation. The researchers used extensive statistical adjustments to reduce confounding, but unmeasured factors could still influence results.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle lipid measurement:\u003c\/strong\u003e Baseline cholesterol was based on a single outpatient lipid panel. Cholesterol levels can change over time, and the study did not capture long-term cholesterol trajectories for most analyses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVeteran population:\u003c\/strong\u003e The study population was predominantly male (about 93% men) and consisted entirely of veterans using VHA services. Results may not fully generalize to women, non-veterans, or populations with different demographic characteristics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUncertain fasting status:\u003c\/strong\u003e Because fasting status was uncertain, the primary analysis focused on total cholesterol and HDL-C. Triglycerides, LDL-C, and non-HDL cholesterol were analyzed only in sensitivity analyses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReverse causality can never be fully excluded:\u003c\/strong\u003e Even with the 2-year lag analysis and comprehensive adjustments, the possibility remains that some unmeasured disease process at baseline influenced both cholesterol levels and mortality risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCHD death as the sole outcome:\u003c\/strong\u003e The study examined death from coronary heart disease specifically. The relationship between cholesterol and other outcomes (such as nonfatal heart attacks, strokes, or total mortality) was not the focus of this analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: Practical Advice for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this research and the broader body of scientific evidence, here are actionable recommendations:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your cholesterol numbers.\u003c\/strong\u003e Talk to your doctor about getting a lipid panel (blood test) that measures total cholesterol, HDL-C, LDL-C, and triglycerides. This study used total cholesterol as the primary measure, but your doctor will consider all fractions to assess your risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't fear low cholesterol.\u003c\/strong\u003e If your cholesterol is low — especially if it's low because you're taking a statin — there is no evidence from this study that this puts you at higher risk of dying from heart disease. The opposite is true.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you are young, pay special attention to high cholesterol.\u003c\/strong\u003e This study found the strongest relative risk associated with very high cholesterol (≥280 mg\/dL) among veterans aged 18–45 years. Early intervention to control cholesterol may yield the greatest lifelong benefit.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTake statins as prescribed.\u003c\/strong\u003e If your doctor has recommended statin therapy, this study provides reassurance that lipid-lowering treatment is safe and effective. Veterans who started statins during follow-up had attenuated risk compared with those who did not.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFocus on overall cardiovascular health.\u003c\/strong\u003e Cholesterol is one important risk factor, but it does not act alone. Blood pressure control, diabetes management, smoking cessation, healthy weight, and regular physical activity all contribute to reducing heart disease risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your doctor about your individual risk.\u003c\/strong\u003e Official guidelines have changed over time regarding who should take statins for primary prevention. Discuss your personal risk profile — including age, cholesterol levels, blood pressure, diabetes status, and family history — with your healthcare provider to make an informed decision.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the cholesterol paradox, and is it a real danger?\u003c\/h3\u003e\n\u003cp\u003eThe cholesterol paradox is the idea that very low cholesterol increases heart disease death risk. In an analysis of 4.4 million U.S. veterans, this appeared only before adjusting for age and illness. After thorough adjustment, low cholesterol carried no increased risk. The apparent danger was explained by reverse causality: older, sicker patients had low cholesterol because of disease.\u003c\/p\u003e\n\u003ch3\u003eShould I worry if my total cholesterol is low?\u003c\/h3\u003e\n\u003cp\u003eNo. In this large veterans study, after accounting for age, chronic diseases, and other factors, low total cholesterol was not associated with any increased risk of dying from coronary heart disease. The higher risk seen in unadjusted analyses was due to underlying illness, not the low cholesterol itself. Low cholesterol from statin use was also not harmful.\u003c\/p\u003e\n\u003ch3\u003eWhat does this research say about statins and low cholesterol?\u003c\/h3\u003e\n\u003cp\u003eIt provides reassurance. Among veterans whose low cholesterol was achieved with statin therapy, there was no paradoxical increase in heart disease death risk. Instead, those who started statins during follow-up had a weaker association between high baseline cholesterol and death, suggesting benefit. The study supports the lipid hypothesis that lower cholesterol is better, even when medication achieves it.\u003c\/p\u003e\n\u003ch3\u003eAt what total cholesterol level does heart disease death risk start to increase?\u003c\/h3\u003e\n\u003cp\u003eIn fully adjusted analyses, the risk of dying from coronary heart disease was flat for total cholesterol below 180 mg\/dL and then rose continuously and steadily above that level. For example, compared with 180–199 mg\/dL, a total cholesterol of 280 or higher was linked to a 45% higher risk of heart disease death.\u003c\/p\u003e\n\u003ch3\u003eDoes age change how cholesterol affects heart disease risk?\u003c\/h3\u003e\n\u003cp\u003eYes. Age significantly modified the relationship. High cholesterol raised heart disease death risk in every age group, but the relative effect was strongest in younger veterans aged 18–45. In that group, total cholesterol of 280 or higher was linked to nearly double the risk compared with normal cholesterol, emphasizing the importance of addressing high cholesterol early.\u003c\/p\u003e\n\u003ch3\u003eIf I already have heart disease, does high cholesterol still matter?\u003c\/h3\u003e\n\u003cp\u003eYes, but the relative effect is somewhat smaller. Veterans with existing heart disease showed the same J-shaped pattern: flat risk at low cholesterol and rising risk at higher cholesterol. However, the increased risk from very high cholesterol was more pronounced in those without preexisting heart disease, because the disease itself strongly influences mortality.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this cholesterol research?\u003c\/h3\u003e\n\u003cp\u003eThis was an observational study, so it cannot prove causation. Baseline cholesterol was a single measurement, fasting status was uncertain, and the population was mostly male veterans, so results may not fully apply to women or non-veterans. Even with careful adjustments, reverse causality from unmeasured disease can never be completely excluded.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before starting statins for high cholesterol?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can help when your doctor recommends statins and your cholesterol is above 180 mg\/dL, because research in over 4 million veterans shows heart disease death risk rises continuously as total cholesterol climbs above that level. Conversely, low cholesterol achieved with statins is not dangerous; the apparent 'cholesterol paradox' reflects reverse causality in older, sicker patients. If you are young, very high cholesterol carries the strongest relative risk, so early treatment decisions matter. An independent expert review can clarify whether your treatment plan fits your individual risk. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e nguyen-et-al-2023-serum-cholesterol-and-impact-of-age-on-coronary-heart-disease-death-in-more-than-4-million-veterans\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Xuan-Mai T. Nguyen, PhD; Yuk-Lam Ho, MPH; Yanping Li, PhD; Rebecca J. Song, PhD; Kenneth H. Leung, MD; Saad Ur Rahman, MBBS; Ariela R. Orkaby, MD, MPH; Jason L. Vassy, MD; David R. Gagnon, MD, PhD; Kelly Cho, PhD; J. Michael Gaziano, MD, MPH; Peter W. F. Wilson, MD\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Journal of the American Heart Association (JAHA), 2023; Volume 12, Article e030496. DOI: 10.1161\/JAHA.123.030496\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication Date:\u003c\/strong\u003e 2023. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivs License.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding and Disclosures:\u003c\/strong\u003e The study was conducted using data from the Veterans Health Administration, with approval from the\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47541989179548,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/zh\/products\/cholesterol-and-heart-disease-death-insights-from-a-study-of-4-5-million-veterans","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}